Spero Therapeutics Stock Performance
| SPRO Stock | USD 2.32 0.18 8.41% |
The entity has a beta of -0.0019, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Spero Therapeutics are expected to decrease at a much lower rate. During the bear market, Spero Therapeutics is likely to outperform the market. At this point, Spero Therapeutics has a negative expected return of -0.056%. Please make sure to validate Spero Therapeutics' coefficient of variation, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if Spero Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Spero Therapeutics is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 7.01 | Five Day Return 2.23 | Year To Date Return (2.55) | Ten Year Return (80.09) | All Time Return (80.09) |
1 | Disposition of 40270 shares by Esther Rajavelu of Spero Therapeutics at 2.37 subject to Rule 16b-3 | 11/07/2025 |
2 | What technical patterns form on Spero Therapeutics Inc. stock charts - Weekly Profit Recap AI Driven Price Forecasts - newser.com | 11/20/2025 |
3 | Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 11/28/2025 |
4 | Can Spero Therapeutics Inc. stock test all time highs - Market Risk Report Free Low Drawdown Momentum Trade Ideas - Newser | 12/04/2025 |
5 | GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics - TipRanks | 12/19/2025 |
6 | Spero Therapeutics Stock Price Crosses Below 200 Day Moving Average - Time to Sell - MarketBeat | 12/23/2025 |
7 | Disposition of 9504 shares by Shukla Sath of Spero Therapeutics at 1.8279 subject to Rule 16b-3 | 01/02/2026 |
8 | Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks | 01/30/2026 |
Spero Therapeutics Relative Risk vs. Return Landscape
If you would invest 246.00 in Spero Therapeutics on November 7, 2025 and sell it today you would lose (14.00) from holding Spero Therapeutics or give up 5.69% of portfolio value over 90 days. Spero Therapeutics is currently does not generate positive expected returns and assumes 2.8435% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Spero, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Spero Therapeutics Target Price Odds to finish over Current Price
The tendency of Spero Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.32 | 90 days | 2.32 | about 69.15 |
Based on a normal probability distribution, the odds of Spero Therapeutics to move above the current price in 90 days from now is about 69.15 (This Spero Therapeutics probability density function shows the probability of Spero Stock to fall within a particular range of prices over 90 days) .
Spero Therapeutics Price Density |
| Price |
Predictive Modules for Spero Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Spero Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Spero Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Spero Therapeutics is not an exception. The market had few large corrections towards the Spero Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Spero Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Spero Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.1 | |
β | Beta against Dow Jones | -0.0019 | |
σ | Overall volatility | 0.10 | |
Ir | Information ratio | -0.06 |
Spero Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Spero Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Spero Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Spero Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 47.98 M. Net Loss for the year was (68.57 M) with loss before overhead, payroll, taxes, and interest of (21.16 M). | |
| Spero Therapeutics currently holds about 45.4 M in cash with (23.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Spero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks |
Spero Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Spero Stock often depends not only on the future outlook of the current and potential Spero Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Spero Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 54 M | |
| Cash And Short Term Investments | 52.9 M |
Spero Therapeutics Fundamentals Growth
Spero Stock prices reflect investors' perceptions of the future prospects and financial health of Spero Therapeutics, and Spero Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Spero Stock performance.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.3 | ||||
| Profit Margin | (1.08) % | ||||
| Operating Margin | (1.35) % | ||||
| Current Valuation | 80.37 M | ||||
| Shares Outstanding | 56.34 M | ||||
| Price To Earning | 81.20 X | ||||
| Price To Book | 4.55 X | ||||
| Price To Sales | 2.97 X | ||||
| Revenue | 47.98 M | ||||
| Gross Profit | (21.16 M) | ||||
| EBITDA | (72.48 M) | ||||
| Net Income | (68.57 M) | ||||
| Cash And Equivalents | 45.4 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 4.3 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.65 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (23.44 M) | ||||
| Earnings Per Share | (0.79) X | ||||
| Market Capitalization | 120.57 M | ||||
| Total Asset | 110.54 M | ||||
| Retained Earnings | (459.64 M) | ||||
| Working Capital | 58.2 M | ||||
| Current Asset | 7.3 M | ||||
| Current Liabilities | 6.04 M | ||||
About Spero Therapeutics Performance
By examining Spero Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Spero Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Spero Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (108.71) | (114.15) | |
| Return On Tangible Assets | (0.56) | (0.59) | |
| Return On Capital Employed | (1.07) | (1.13) | |
| Return On Assets | (0.56) | (0.59) | |
| Return On Equity | (1.34) | (1.40) |
Things to note about Spero Therapeutics performance evaluation
Checking the ongoing alerts about Spero Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Spero Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Spero Therapeutics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 47.98 M. Net Loss for the year was (68.57 M) with loss before overhead, payroll, taxes, and interest of (21.16 M). | |
| Spero Therapeutics currently holds about 45.4 M in cash with (23.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29. | |
| Spero Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Spero Therapeutics Co-Founder Resigns From Board Roles - TipRanks |
- Analyzing Spero Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Spero Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Spero Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Spero Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Spero Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Spero Therapeutics' stock. These opinions can provide insight into Spero Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spero Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.